JBTM Stock Analysis: JBTMarel | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 7.593m USD | 12M Return: 10.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 71.8M
EPS Trend: -38.7%
Qual. Beats: 0
Rev. Trend: 85.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
JBT Marel Corporation (NYSE: JBTM) is a global supplier of technology, equipment, software, and services to the food and beverage processing industry, operating two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions. Its product range covers nearly the full processing workflow, from stunning and slaughter through cooking, freezing, pasteurizing, and final packaging. The company also produces automated guided vehicle (AGV) systems used for material handling in automotive plants, warehouses, and medical facilities.
The business serves a broad customer base across poultry, beef, pork, seafood, dairy, bakery, ready-to-eat meals, plant-based proteins, pet food, and beverage categories, selling through a mix of direct sales, independent distributors, sales representatives, and technical service teams. As a mid-cap Industrial Machinery & Components company, JBT Marels revenue is tied to capital spending by food processors, which tends to follow long-cycle trends in protein consumption, food safety regulation, and plant automation rather than short-term consumer demand.
The company is headquartered in Chicago, Illinois, was incorporated in 1994, and IPOd in 2008. It was previously known as John Bean Technologies Corporation and adopted the JBT Marel name in January 2025 following the combination with Iceland-based Marel, which expanded its global footprint across the U.S., Canada, Europe, the Middle East, Africa, Asia Pacific, and Latin America.
- Protein Solutions segment revenue grows on poultry processing demand
- Marel merger synergies and integration drive margin expansion
- European and Asia Pacific demand supports equipment backlog growth
| Net Income: 167.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.28 > 1.0 |
| NWC/Revenue: 0.46% < 20% (prev 14.01%; Δ -13.55% < -1%) |
| CFO/TA 0.05 > 3% & CFO 426.3m > Net Income 167.5m |
| Net Debt (1.61b) to EBITDA (556.1m): 2.90 < 3 |
| Current Ratio: 1.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.4m) vs 12m ago 1.35% < -2% |
| Gross Margin: 35.34% > 18% (prev 35.76%; Δ -0.42% > 0.5%) |
| Asset Turnover: 48.01% > 50% (prev 27.22%; Δ 20.79% > 0%) |
| Interest Coverage Ratio: 3.86 > 6 (EBIT TTM 289.6m / Interest Expense TTM 75.1m) |
| A: 0.00 (Total Current Assets 1.68b - Total Current Liabilities 1.66b) / Total Assets 8.16b |
| B: 0.18 (Retained Earnings 1.50b / Total Assets 8.16b) |
| C: 0.04 (EBIT TTM 289.6m / Avg Total Assets 8.08b) |
| D: 1.22 (Book Value of Equity 4.48b / Total Liabilities 3.68b) |
| Altman-Z'' = 2.14 = BBB |
| DSRI: 0.60 (Receivables 580.0m/543.9m, Revenue 3.88b/2.18b) |
| GMI: 1.01 (GM 35.76% / 35.34%) |
| AQI: 0.97 (AQ_t 0.70 / AQ_t-1 0.72) |
| SGI: 1.78 (Revenue 3.88b / 2.18b) |
| TATA: -0.03 (NI 167.5m - CFO 426.3m) / TA 8.16b) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at USD 138.92 with a total of 621,255 shares traded. Over the past week, the price has changed by -4.19%, over one month by +12.13%, over three months by +6.72% and over the past year by +10.94%.
Current recommended Stop Loss: 132.20 (which is 4.8% or 1.3 ATR below the current price).
JBTMarel has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold JBTM.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 178.8 | 28.7% |
P/E Trailing = 44.8708
P/E Forward = 18.622
P/S = 1.9569
P/B = 1.6937
P/EG = 1.2201
Revenue TTM = 3.88b USD
EBIT TTM = 289.6m USD
EBITDA TTM = 556.1m USD
Long Term Debt = 1.43b USD (from longTermDebt, last quarter)
Short Term Debt = 411.0m USD (from shortTermDebt, last quarter)
Debt = 1.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.61b USD (calculated: Debt 1.84b - CCE 230.0m)
Enterprise Value = 9.21b USD (7.59b + Debt 1.84b - CCE 230.0m)
Interest Coverage Ratio = 3.86 (Ebit TTM 289.6m / Interest Expense TTM 75.1m)
EV/FCF = 29.07x (Enterprise Value 9.21b / FCF TTM 316.7m)
FCF Yield = 3.44% (FCF TTM 316.7m / Enterprise Value 9.21b)
FCF Margin = 8.16% (FCF TTM 316.7m / Revenue TTM 3.88b)
Net Margin = 4.32% (Net Income TTM 167.5m / Revenue TTM 3.88b)
Gross Margin = 35.34% ((Revenue TTM 3.88b - Cost of Revenue TTM 2.51b) / Revenue TTM)
Gross Margin QoQ = 35.15% (prev 34.53%)
Tobins Q-Ratio = 1.13 (Enterprise Value 9.21b / Total Assets 8.16b)
Interest Expense / Debt = 4.07% (Interest Expense 75.1m / Debt 1.84b)
Taxrate = 21.43% (45.9m / 214.2m)
NOPAT = 227.5m (EBIT 289.6m * (1 - 21.43%))
Current Ratio = 1.01 (Total Current Assets 1.68b / Total Current Liabilities 1.66b)
Debt / Equity = 0.41 (Debt 1.84b / totalStockholderEquity, last quarter 4.48b)
Debt / EBITDA = 2.90 (Net Debt 1.61b / EBITDA 556.1m)
Debt / FCF = 5.09 (Net Debt 1.61b / FCF TTM 316.7m)
Total Stockholder Equity = 4.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.07% (Net Income 167.5m / Total Assets 8.16b)
RoE = 3.78% (Net Income TTM 167.5m / Total Stockholder Equity 4.44b)
RoCE = 4.94% (EBIT 289.6m / Capital Employed (Equity 4.44b + L.T.Debt 1.43b))
RoIC = 3.38% (NOPAT 227.5m / Invested Capital 6.72b)
WACC = 8.71% (E(7.59b)/V(9.44b) * Re(10.05%) + D(1.84b)/V(9.44b) * Rd(4.07%) * (1-Tc(0.21)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.89 | Cagr: 24.33%
[DCF] Terminal Value 76.80% ; FCFF base≈273.1m ; Y1≈313.0m ; Y5≈460.7m
[DCF] Fair Price = 94.19 (EV 6.52b - Net Debt 1.61b = Equity 4.90b / Shares 52.1m; r=8.71% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -38.74 | EPS CAGR: -23.93% | SUE: 0.07 | # QB: 0
Revenue Correlation: 85.54 | Revenue CAGR: 37.90% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.02 | Chg30d=-4.46% | Revisions=-57% | Analysts=6
EPS next Quarter (2026-09-30): EPS=2.31 | Chg30d=-2.31% | Revisions=-38% | Analysts=6
EPS current Year (2026-12-31): EPS=8.28 | Chg30d=+0.97% | Revisions=+57% | GrowthEPS=+29.2% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=9.36 | Chg30d=+0.83% | Revisions=+17% | GrowthEPS=+13.0% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -11% (up=7, down=9)